logo

CRMD

CorMedix·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

CRMD fundamentals

CorMedix (CRMD) released its earnings on Nov 12, 2025: revenue was 104.28M (YoY +810.27%), beat estimates; EPS was 1.26 (YoY +2620.00%), beat estimates.
Revenue / YoY
104.28M
+810.27%
EPS / YoY
1.26
+2620.00%
Report date
Nov 12, 2025
CRMD Earnings Call Summary for Q3,2025
  • Record Q3 Performance: $104.3M revenue, $108.6M net income, $71.8M EBITDA - all records.
  • Synergy Capture: $30M of $35-45M annual synergies achieved ahead of schedule.
  • Pipeline Catalysts:
    • Rezeo phase 3 fungal prophylaxis data Q2 2026 ($2B TAM).
    • DefenCath TPN phase 3 completion 2026/27 ($750M TAM).
  • Post-TDAPA Strategy:
    • Medicare Advantage partnerships leveraging real-world evidence.
    • CMS ESRD rule expected Q1 2026 to set 2026/27 pricing.
EPS
Revenue

Revenue & Expenses

CRMD has released its 2025 Q3 earnings report, with revenue of 104.28M, reflecting a YoY change of 810.22%, and net profit of 108.56M, showing a YoY change of 4009.63%. The Sankey diagram below clearly presents CRMD's revenue sources and cost distribution.

Key Indicators

CorMedix (CRMD) key financial stats and ratios, covering profitability, financial health, and leverage.
CorMedix (CRMD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
CorMedix (CRMD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
CorMedix (CRMD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does CorMedix (CRMD) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track CorMedix (CRMD) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield